Soluble guanylate cyclase stimulators in pulmonary hypertension.
about
The molecular targets of approved treatments for pulmonary arterial hypertensionExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSInterfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysmSoluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.Riociguat for pulmonary arterial hypertension associated with congenital heart disease.Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal womenEvaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.Identification of downstream target genes regulated by the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signal pathway in pulmonary hypertension.ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism.Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension.Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.Riociguat: PATENT-1 Study.Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Clinical implications of riociguat pharmacokinetics and pharmacodynamics: introduction to the riociguat clinical pharmacology supplement.Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review.Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.
P2860
Q26798308-A4E6CDD7-AE93-4B53-A293-866C1A66E972Q27021649-A4CF68B4-8889-4C23-966C-3AE4B2B9BEFDQ27682500-80C51313-1EC6-4B25-9500-1CA751D7813DQ33596457-7CD59F43-E0C4-400C-8C99-F6571EA67045Q34042836-063125FD-7E8D-4019-B840-7FD8662F3924Q34627792-12CD3015-D19E-4A89-B930-B70C9B3CF46AQ35075847-E2545720-1249-4B3C-AA17-11867DEDFC1EQ36363156-59DE28E1-9919-45B5-AE91-29CAD2B36B19Q36374793-55AE3FDF-690A-458B-BD5F-8DD4BA0AC780Q36766005-4FA40281-A31C-4B07-A96B-5237C3491BE1Q36881711-17E755F2-F404-49B3-A56F-AE077AF674F9Q36881728-F0E4C0BA-7143-499C-9412-00245DD3A773Q37510689-DEAF4C2D-E8F7-4FFA-9ADF-26275DB23F9EQ37616946-36D78013-F029-4670-A29B-BF31EC67E701Q37697630-5E0A7C62-2D30-4C89-91E0-4C7A882549DBQ38448924-A6D37CAA-86A3-4DB0-987C-48CE06D7318BQ38656360-0CAB9016-A8A0-4400-B7A0-8D1529B9AC1FQ39419466-52A24036-BCB7-4E08-9A01-839D6A04B696Q41143611-E07205D6-B75B-4D4F-ACC6-00CD3CBAC385Q41980644-FD859521-CA71-477B-AA1C-485387D2CB5EQ42244904-55333187-0674-4E7E-82FD-6F9EBA824DA7Q43119916-25CF4D78-A920-4537-B67B-DCEA99B41983Q45906325-01149B22-2AE7-4600-B680-7DD1DCFEC7E0Q47561539-B72CF39A-B07B-46E9-9859-C513F9E09D08Q47584698-28689D0C-8746-49C0-AC4F-33F0592F2F53Q47661369-C53142BB-C3C9-4238-8106-987A9A8562C4Q47845345-0D94D0BB-EED1-4B24-8C3C-602DC57EF144Q52670776-D83C35DF-34AD-4BC9-B420-0E6FBC1DA6A4Q53835859-924F598B-15EC-4D8A-BFD3-239E4F6AD616
P2860
Soluble guanylate cyclase stimulators in pulmonary hypertension.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Soluble guanylate cyclase stimulators in pulmonary hypertension.
@en
type
label
Soluble guanylate cyclase stimulators in pulmonary hypertension.
@en
prefLabel
Soluble guanylate cyclase stimulators in pulmonary hypertension.
@en
P921
P1476
Soluble guanylate cyclase stimulators in pulmonary hypertension.
@en
P2093
Oleg V Evgenov
P304
P356
10.1007/978-3-642-38664-0_12
P577
2013-01-01T00:00:00Z